Supernus Pharmaceuticals, Inc.
SUPN
$50.32
$0.410.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 21.48% | 9.34% | -1.71% | 4.30% | 5.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.48% | 9.34% | -1.71% | 4.30% | 5.99% |
| Cost of Revenue | -2.50% | 3.67% | -6.08% | -3.35% | -375.39% |
| Gross Profit | 16.99% | 11.39% | -1.19% | 5.28% | 57.73% |
| SG&A Expenses | 141.84% | 36.58% | 10.07% | 9.05% | 0.40% |
| Depreciation & Amortization | 34.43% | 24.82% | 3.54% | -1.74% | -13.41% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 76.41% | 24.61% | 2.80% | 6.04% | 6.38% |
| Operating Income | -412.62% | -70.08% | -38.83% | -64.69% | 3.01% |
| Income Before Tax | -107.25% | -228.95% | -36.62% | -2,499.59% | 2,564.85% |
| Income Tax Expenses | -80.18% | -299.15% | -191.29% | 4,938.66% | 6,075.14% |
| Earnings from Continuing Operations | -126.78% | -217.20% | 12.97% | -9,637.90% | 1,204.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -126.78% | -217.20% | 12.97% | -9,637.90% | 1,204.51% |
| EBIT | -412.62% | -70.08% | -38.83% | -64.69% | 3.01% |
| EBITDA | -194.09% | -31.28% | -16.52% | -18.87% | -5.56% |
| EPS Basic | -125.90% | -214.30% | 10.88% | -9,304.35% | 1,185.58% |
| Normalized Basic EPS | -331.44% | -67.67% | -29.94% | -196.91% | 15.21% |
| EPS Diluted | -126.71% | -215.94% | 11.11% | -9,722.73% | 1,446.86% |
| Normalized Diluted EPS | -335.62% | -67.16% | -29.77% | -200.00% | 14.51% |
| Average Basic Shares Outstanding | 3.39% | 2.54% | 1.90% | 1.94% | 1.50% |
| Average Diluted Shares Outstanding | 1.56% | 0.96% | 1.65% | 0.43% | 2.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |